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Receptor-mediated Cellular Uptake of Cyclosporlne 
Ajit Sanghvi, Vijay S. Warty, Warren F. Diven, and Thomas Starzl 
THE PROCESS of cellular uptake and metabolism of 
cyclosporine (CsA) is poorly understood. Earlier stud-
ies in this laboratory indicated that transport of CsA in blood 
occurs in association with plasma lipoproteins, with low 
density lipoprotein (LDL) and high density lipoprotein 
(HOL) carrying about 32% each of the total CsA in blood. 
This observation suggests the possibility that the cellular 
uptake of CsA may occur through the LDL receptor path-
way. To further identify this phenomenon, we incubated 
CsA-LOL complex with freshly isolated peripheral blood 
lymphocytes (PBL) and also with PBL in which LDL 
receptors synthesis was enhanced by incubation in lipid free 
serum. Results of these experiments show that cellular 
uptake of CsA is increased about 25% in cells incubated in 
lipid-free serum relative to controls. This increased uptake of 
CsA could be in part due to the proliferation of LDL recep-
tors in the stimulated cells. Since at least 32% of the drug 
circulates in association with LDL, this pathway provides an 
important mechanism for the meta bolism of CsA. 
The aims of this study were to examine the kinetics of 
binding and uptake of CsA by the human peripheral blood 
lymphocytes. and the enhancement of CsA uptake by periph-
eral blood lymphocytes via LOL receptor pathway. 
Cyclosporine (CsA) is widely used in transplantation as 
the immunosuppressive agent of choice. In our earlier stud-
ies. we have shown that transport of CsA in blood occurs 
mainly in association with plasma lipoproteins. 70% of the 
drug being in LDL and HOL fractions.! This suggests that 
cellular uptake and metabolism of CsA may. at least in part. 
follow the lipoprotein metabolism. specifically. the LOL-
receptor mediated pathway. 
MATERIALS AND METHODS 
Tritiated dihydrocyclosporine A (CsA) (60 mCi/mmol) and CsA 
standards were obtained from Sandoz. Ltd (Basel. Switzerland) as 
ethanolic solutions. FK506 was a gift from Fujisawa Pharmaceutical 
Co. Ltd (Osaka. lapan). Methanolic solution of FK506 was used in 
the experiments. Culture media and antibiotics were obtained from 
GIBCO (Grand Island. NY). All other reagents and supplies were 
from Fisher Scientific Co. Pittsburgh. 
Human LDL (d - 1.019 to 1.063) was prepared from blood 
collected in 0.1 % EOT A from healthy subjects who had fasted 
overnight. Lipoproteins were fractionated by sequential floatation in 
a Beckman preparative ultracentrifuge (Beckman Instruments. Inc. 
Fullerton. CAl according to Havel et aLl Protein determinations 
were performed by the Bradford method. 
Peripheral blood mononuclear cells were isolated as previously 
described) from approximately 100 ml of blood obtained from 
healthy volunteers for each experiment. The monocyte content of 
these cells was depleted by the method of lerrells et a!. Cell viability 
was assessed by using the dye exclusion method. 
LOL (100 I'g in 1 ml RPMI 1640 medium) was added dropwise 
with stirring to an ethanolic [IHJ CsA solution (50 Ill). The mixture 
was incubated with constant shaking for one hour at room tempera-
ture. The specific activity of the eHJ CsA-LOL complex thus 
obtained in three separate preparations was 20 ± 0.8 x 10' dpm/Ilg 
LOL. 
lymphocytes were incubated in RPMI 1640 medium containing 
1 % bovine serum albumin (BSA) in the presence or absence of CsA 
and/or FK506 for 24 hours. After these preincubations, the cells 
were washed twice with ice-cold 0.85% NaCI solution and then 
resuspended in 1% BSA-RPMI medium. The cells were placed in 
culture wells (10' cells/well) and exposed to increasing molar 
concentrations of [IHJ CsA (specific activity. 900 to 1, I 00 dpm/ 
pmol) and equivalent concentrations of cold CsA and FK506. as 
indicated in the legends to the figures. for one hour at 37°C in the 
humidified atmosphere of 95% O2:5% CO2, Transport flux was 
stopped by adding ice-cold saline and cooling the mixture further for 
ten minutes over ice. The cells were washed three times with cold 
saline and incubated in 0.2 mL I N KOH for one hour at 70° C. The 
digested solution was used for the measurement of radioactivity and 
protein determinations. 
RESULTS 
CsA uptake by lymphocytes from two healthy donors was 
studied by incubating cells with the [lHJ CsA-LDL complex. 
The kinetics of the uptake of CsA in these experiments are 
shown in Figure I. panels A and B. In both individuals 
studied. the CsA uptake appears to reach saturation at an 
LDL concentration of about 50 Ilg/ml medium. The corre-
sponding CsA concentration is about 900 ng/mL. In a 
previous studyl on the cell surface binding and subsequent 
metabolism of LOL by T and B lymphocytes. we have 
observed that the LOL receptor is saturated at 50 Ilg 
LOL/ml medium. Moreover. [lHJ CsA uptake by lympho-
cytes was suppressed in the presence of cold CsA and LOL. 
Combined. these observations suggest that internalization of 
lipoprotein-associated CsA may occur via the high-affinity 
specific receptor for LOL on the cell surface. The experimen-
tal conditions used in these studies imply that the CsA 
measurements shown reflect both the processes of cell sur-
face binding and internalization. 
When the cell content of CsA was compared in an 
experiment in which two sets of lymphocytes obtained from 
the same donor were incubated simultaneously with various 
concentrations of CsA alone or with CsA-LDL complex it 
was observed that cells incubated with CsA-LOL contained 
greater amounts of CsA at each of the concentrations 
studied. Quite importantly. internalization of CsA from 
CsA-LOL complex during the initial phase was 45% higher 
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Fig. 1. Cellular uptake of CsA In PBl Incubated with the [IHJ 
CaA-LDl complex for one hour. The open and closed symbols 
r.present the total and nonspecific (LDl receptor·lndepen-
dent) uptake of [IH] CsA, respectively. Panels A and Bar. 
r.,ult, In two subjects. 
relative to control. When the receptor and internalization 
processes were saturated this difference stabilized at 18% as 
shown in Figure 2. 
Cellular CsA uptake in the absence of LOL was studied in 
lymphocytes from two healthy volunteers (other than for 
Figs 1 and 2). The results of the experiments shown in Fig 3. 
panels A and B. indicate that, as in the presence of LOL, 
(lH]CsA uptake in this instance may also involve a saturable 
process. 
DISCUSSION 
The cellular uptake of CsA appears to involve both specific 
was well as nonspecific processes. the former taking place 
when the drug is associated with lipoprotein. In this instance. 
the CsA-LOL complex may be internalized via the high-
affinity. specific cell surface receptor for LOL. 
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Fig. 2. lymphocytes were prelncubated In 1°,," BSA In RPMI 
1640 for 24 hours. Cells were then exposed with CsA (A-A) 
and CsA· lDl complex (A-A) and cellular uptake of [3HJ CsA 
was measured. 
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FIg. 3. Cellular uptake of CsA In PBl Incubated with [3H] CsA 
(0-0) and unlabeled CsA (A-A). Panels A and B are results 
In two subjects. 
Support for this concept also derives partly from the 
calculations of dissociation constants for various experiments 
reported here. The double reciprocal plots of data from these 
experiments yield two quite distinct apparent dissociation 
constants (KD)' For the cellular uptake of CsA complexed 
with LOL. KD ~ 2.3 and 0.6 x 10- 9 mol/l (Fig I, panels A 
and B, respectively). For the data in all of the rest of the 
experiments, KD = 2 x 1O-7mol/l. The Ko of 10- 9 mol/l for 
CsA when in association with LOL certainly suggests high-
affinity binding. The rate-limiting step in the LOL pathway 
is the binding of LOL to a specific high-affinity receptor on 
the cell surface.' It may be expected. therefore. that this 
would be the initial step in the metabolism of CsA bound to 
LOL. The significantly reduced cellular content of [lH] CsA 
in the presence of cold LOL appears to strengthen this view. 
Whether such a binding of CsA-LOL to the LOL receptor 
followed by further metabolism along the LOL pathway 
occurs cannot be inferred from the experiments reported 
here. If true. however. it could represent a significant path-
way for CsA metabolism because some 32'7c of the drug in 
blood is bound to plasma LOL. 1 The concentrations of CsA 
required to saturate the cellular mechanisms(s) responsible 
for CsA uptake are also different in the presence and absence 
of LOL. 900 ng/ml with LOL and about 300 ng/ml without 
LOL. This information further segregates the two processes. 
CONCLUSIONS 
Cyclosporinc uptake by peripheral blO<..1d lymphocytes may 
involve specific as well as nonspecific processes. In either 
case. the kinetics of uptake indicate a saturable phenomenon 
implying the involvement of a "carrier" or "transport" 
protein. Cyclosporine uptake by cells when associated with 
LOL was greater relative to the uptake of cyclosporine alone. 
The dissociation constant for CsA-LOL complex of 10- 9 M 
suggests high affinity binding. perhaps to the LOL receptor. 
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